aldose reductase

Alconil (Al 1567) is an aldose reductase inhibitor that may be used to study chronic obstructive pulmonary disease (COPD) and diabetes.

Isoliquiritigenin (ISL) is a flavonoid natural product that inhibits influenza virus replication (EC50=24.7 μM) and aldose reductase activity (IC50=320 nM). Isoliquiritigenin has antitumor activity.

Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.

DL-Glyceraldehyde (Glyceric aldehyde) is produced from the action of the enzyme glyceraldehyde dehydrogenase, which converts glycerol to glyceraldehyde using NADP as a cofactor. When present at sufficiently high levels, DL-Glyceraldehyde can be a cytotoxin and a mutagen. A cytotoxin is a compound that kills cells. A mutagen is a compound that causes mutations in DNA. DL-Glyceraldehyde is a highly reactive compound that can modify and cross-link proteins. DL-Glyceraldehyde modified proteins appear to be cytotoxic, depress intracellular glutathione levels, and induce reactive oxygen species (ROS) production (PMID: 14981296 ). DL-Glyceraldehyde has been shown to cause chromosome damage to human cells in culture and is mutagenic in the Ames bacterial test.

2-Chloro-1-(4-fluorobenzyl)benzimidazole is an inhibitor of aldose reductase (ALR2).

EBPC is an inhibitor of aldose reductase.

6-Methoxytricin, a flavonoid isolated from Centella asiatica, is an inhibitor of aldose reductase (AR) and advanced glycosylation end-products (AGE), and inhibits T-cell proliferation and activation in biologic cells.

Fidarestat (SNK 860), an aldose reductase inhibitor, exhibits IC50 values of 26 nM, 33 μM, and 1.8 μM against aldose reductase, AKR1B10, and V301L AKR1B10 respectively, demonstrating potential for diabetes treatment.

Sorbinil is an Aldose reductase inhibitor. Sorbinil plays a therapeutic role in treating diabetes and diabetic complications decreases AR activity and inhibit the polyol pathway.

Ponalrestat is an aldose reductase inhibitor.

Tectoridin (Shekanin) possesses an estrogenic and thyroid hormone-like agent by activating estrogen and thyroid hormone receptors. Tectoridin has anti-oxidant, anti-inflammatory and hypoglycemic activities; Tectoridin and its five metabolites inhibits the activities of lens aldose reductase in rat (IC : 1.4-15.5 μM).

Alrestatin (AY-22284) is a specific inhibitor of aldose reductase and attenuates glucose-induced angiotensin II production in rat vascular smooth muscle in vitro.

1. Ganoderic acid C6 has antinociceptive activity.

2'-Acetylacteoside has antioxidative activity. It can significantly attenuate glutamate-induced neurotoxicity at concentrations ranging from 0.1 to 10 μM. 2'-Acetylacteoside shows antiproliferative effects on aortic smooth muscle, indicates that it may ha

Poliumoside is a natural compound which exhibits significant inhibition of advanced glycation end product formation with IC50 value of 4.6-25.7 μM, it also exhibits great inhibitory effects on rat lens aldose reductase with IC50 values of 0.85 μM.Poliumos

WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.WJ-39 inhibits oxidative stress and inhibits the activation of the inflammatory vesicle of the oligomerization structural domain-like receptor family, pyrin structural domain 3 (NLRP3).

Ganoderic acid C2 has anti-inflammatory,and anti-tumor-promoting activities. Ganoderic acid C2 can inhibit histamine release, it also has inhibitory effects on the induction of Epstein-Barr Virus early antigen.

Triptocalline A, a compound from Salacia chinensis, inhibits rat lens aldose reductase.

ALR2-IN-1 is a potent and selective ALR2 inhibitor with an IC50 value of 1.42 μM. ALR2-IN-1 possesses both antiglycemic and antioxidant activities and can be used to study the complications of diabetes.

Aldose reductase-IN-1 (AT-001, Caficrestat) is a highly potent inhibitor of aldose reductase with an IC50 value of 28.9 pM, which can target the relaxin hormone signaling pathway in prostate cancer models.

Aldose reductase-IN-4 (compound IIc) is an inhibitor of aldose reductase with IC50 values of 11.70 μM for ALR1 and 0.98 μM for ALR2, respectively [1].

Aldose reductase-IN-5 is an inhibitor of aldose reductase (ALR2) that enhances the combination of inhibitory excitability and antioxidant capacity, thereby delaying the diabetes complications progress.

Aldose reductase-IN-6 (Compound 3) is a competitive inhibitor of aldose reductase (AR) with an IC50 of 3.164 μM and a Ki of 0.018 μM. Notably, Aldose reductase-IN-6 demonstrates no cytotoxicity toward normal cells [1].

Aldose reductase-IN-3 (Compound 5) is an effective and moderately selective aldose reductase (AR) inhibitor (IC50=3.99 μM) with research potential in sepsis, a molecular target involved in various inflammatory diseases (including sepsis).